| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The molecular target of Minimolide F has not been definitively identified. As a sesquiterpene lactone, it may act through alkylation of nucleophilic groups (such as thiol groups in cysteine residues) on proteins, affecting various signaling pathways. This alkylation can lead to the inhibition of key enzymes involved in inflammation and cell proliferation.
|
|---|---|
| ln Vitro |
Minimolide F can stop the proliferation of CNE cells since it possesses antiproliferative properties[1].
Minimolide F shows antiproliferative activity against human nasopharyngeal cancer cells with an IC50 of 17.4 μM. It can stop the proliferation of CNE cells. It has demonstrated anti-inflammatory, antioxidant, and potential anticancer activities. |
| ln Vivo |
In vivo activity data for Minimolide F are not available in the public literature.
|
| Enzyme Assay |
Non-cell-based assays for Minimolide F could involve measuring its ability to inhibit specific enzymes or its binding to potential protein targets. For example, its antioxidant activity could be assessed using DPPH or ABTS radical scavenging assays. Its anti-inflammatory activity could be evaluated by measuring its ability to inhibit the activity of enzymes such as COX-1, COX-2, or 5-LOX in cell-free systems. However, no specific protocols are described in the available literature.
|
| Cell Assay |
CNE cells (human nasopharyngeal cancer cell line) are treated with Minimolide F at various concentrations (e.g., 0.1-100 µM) for 24-72 hours. Cell proliferation is measured using MTT or CCK-8 assays. The IC50 value of 17.4 µM is determined from the dose-response curve.
|
| Animal Protocol |
In vivo animal studies for Minimolide F have not been reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Minimolide F are not available.
|
| Toxicity/Toxicokinetics |
Toxicological data for Minimolide F are not available.
|
| References | |
| Additional Infomation |
Minimolide F is a natural product with potential anticancer activity. It is isolated from Centipeda minima, a plant used in traditional medicine. It is a guaianolide-type sesquiterpene lactone with a molecular weight of 334.41. It is intended for research use only.
|
| Molecular Formula |
C19H26O5
|
|---|---|
| Molecular Weight |
334.41
|
| Exact Mass |
334.178
|
| CAS # |
1367351-41-4
|
| PubChem CID |
101574680
|
| Appearance |
White to off-white solid
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
465.4±45.0 °C at 760 mmHg
|
| Flash Point |
204.2±28.8 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.536
|
| Source |
Originated from plants: Leguminosae Euchresta horsfieldii (Lesch.) J. Benn.
Originated from plants: Compositae |
| LogP |
2.1
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
24
|
| Complexity |
625
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
CC(C)C(=O)OC1CC2(C)OC22CC3C(CC(C)C12)OC(=O)C3=C
|
| InChi Key |
PZGAEBIPXRQKFC-PZSYGAARSA-N
|
| InChi Code |
InChI=1S/C19H26O5/c1-9(2)16(20)23-14-8-18(5)19(24-18)7-12-11(4)17(21)22-13(12)6-10(3)15(14)19/h9-10,12-15H,4,6-8H2,1-3,5H3/t10-,12-,13-,14+,15-,18-,19+/m1/s1
|
| Chemical Name |
[(1S,3R,7R,9R,10R,11S,13R)-9,13-dimethyl-4-methylidene-5-oxo-6,14-dioxatetracyclo[8.4.0.01,13.03,7]tetradecan-11-yl] 2-methylpropanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~149.5 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.74 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9903 mL | 14.9517 mL | 29.9034 mL | |
| 5 mM | 0.5981 mL | 2.9903 mL | 5.9807 mL | |
| 10 mM | 0.2990 mL | 1.4952 mL | 2.9903 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
